ARCUTIS BIOTHERAPEUTICS, INC. Operating Lease, Payments
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Operating Lease, Payments of $1.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-25
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2023-12-31 was $242.00K, a 3.42% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2023-09-30 was $241.00K, a 23.59% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2023-06-30 was $241.00K, a 36.93% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2023-03-31 was $241.00K, a 36.93% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2025 was $1.03M, a 3.32% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2024 was $994.00K, a 3.01% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2023 was $965.00K, a 23.56% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2022 was $781.00K, a 585.09% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.03M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $994.00K 10-K · filed 2026-02-25 | |||
| 2023-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $483.00K derived: sum of 2 quarters · filed 2026-02-25 | $724.00K derived: sum of 3 quarters · filed 2026-02-25 | $965.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | $241.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $482.00K derived: sum of 2 quarters · filed 2023-11-03 | $723.00K 10-Q · filed 2023-11-03 | $957.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $241.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $482.00K 10-Q · filed 2023-08-08 | $716.00K derived: sum of 3 quarters · filed 2025-02-25 | $911.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $241.00K 10-Q · filed 2023-05-09 | $475.00K derived: sum of 2 quarters · filed 2025-02-25 | $670.00K derived: sum of 3 quarters · filed 2025-02-25 | $846.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $429.00K derived: sum of 2 quarters · filed 2025-02-25 | $605.00K derived: sum of 3 quarters · filed 2025-02-25 | $781.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $195.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $371.00K derived: sum of 2 quarters · filed 2023-11-03 | $547.00K 10-Q · filed 2023-11-03 | $661.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $352.00K 10-Q · filed 2023-08-08 | $466.00K derived: sum of 3 quarters · filed 2024-02-27 | $466.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $176.00K 10-Q · filed 2023-05-09 | $290.00K derived: sum of 2 quarters · filed 2024-02-27 | $290.00K derived: sum of 3 quarters · filed 2024-02-27 | $290.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $114.00K derived: sum of 2 quarters · filed 2024-02-27 | $114.00K derived: sum of 3 quarters · filed 2024-02-27 | $114.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $48.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $48.00K derived: sum of 3 quarters · filed 2023-02-28 | $96.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $48.00K derived: sum of 2 quarters · filed 2023-02-28 | $96.00K derived: sum of 3 quarters · filed 2023-02-28 | $145.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $96.00K derived: sum of 2 quarters · filed 2023-02-28 | $145.00K derived: sum of 3 quarters · filed 2023-02-28 | $192.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $97.00K derived: sum of 2 quarters · filed 2021-11-04 | $144.00K 10-Q · filed 2021-11-04 | $191.00K derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $96.00K 10-Q · filed 2021-08-05 | $143.00K derived: sum of 3 quarters · filed 2022-02-22 | $190.00K derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $47.00K 10-Q · filed 2021-05-06 | $94.00K derived: sum of 2 quarters · filed 2022-02-22 | $141.00K derived: sum of 3 quarters · filed 2022-02-22 | $172.00K derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $94.00K derived: sum of 2 quarters · filed 2022-02-22 | $125.00K derived: sum of 3 quarters · filed 2022-02-22 | $141.00K 10-K · filed 2022-02-22 |
| 2019-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $78.00K derived: sum of 2 quarters · filed 2020-11-05 | $94.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $47.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $16.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |